The recent downturn has taken Alexion Pharmaceuticals shares close to a medium term support level around 95 USD. The timing for a long trade in the stock appears good. Investors have an opportunity to buy the stock and target the $ 107.65.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 94.63 USD in weekly data.
Share prices are approaching a strong support area in daily data, which offers good timing for investors.
Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 45% by 2021.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's attractive earnings multiples are brought to light by a P/E ratio at 11.28 for the current year.
Sales forecast by analysts have been recently revised upwards.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
With an enterprise value anticipated at 4.3 times the sales for the current fiscal year, the company turns out to be overvalued.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.